 with 6.71 qualityadjusted life-years for CEA, with signiÔ¨Åcantly higher costs
for CAS.669 Similarly, the Canadian health system database was used to carry out a cost utility analysis among
symptomatic patients using a Markov analytical model.
In the base case analysis, CAS was noted to be more
costly (incremental cost of $6107) and have a lower utility
(e0.12 quality-adjusted life-years